Latest Anti-diabetic drug Stories
YINCHUAN, China, July 14 /PRNewswire-Asia/ -- Recently, Xinhua Website reported about Dr. Nie Wentao's nutrition intervention technology for type 1 diabetes mellitus. Dr.
ORLANDO, Fla. and CARLSBAD, Calif., June 29 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that data from seven programs in Isis' broad metabolic disease franchise were presented at the American Diabetes Association's (ADA) 70th Scientific Sessions in Orlando.
TOKYO, June 28 /PRNewswire/ -- Astellas Pharma Inc.
SAN DIEGO, June 17 /PRNewswire/ -- Profil(TM) Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the appointment of Prof. Dr. Lutz Heinemann as Director of Scientific Services and Robert J.
KALAMAZOO, Mich., June 15 /PRNewswire/ -- Metabolic Solutions Development Company (MSDC) will present its research providing insights into the mechanisms and novel activities of its drug portfolio at the American Diabetes Association's (ADA) 70th annual Scientific Sessions conference in Orlando, Fla., which is being held on June 25-29, 2010.
New study suggests that medication used to control blood sugar levels can distort results of some molecular imaging screenings for cancer.
If you think of diabetes onset like an elaborate molecular drama, then a research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion.
PRINCETON, N.J., May 6 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) announced today details of the company's cardiovascular outcomes trial for VictozaÂ® (liraglutide [rDNA origin] injection), which is set to start in the autumn of 2010.
An experimental oral drug has lowered blood sugar levels and inflammation in mice with Type 2 diabetes, suggesting that the medication could someday be added to the arsenal of drugs used by millions of Americans with this disease, according to new research.
EAST HANOVER, N.J., March 14 /PRNewswire/ -- Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition. Primary data from the NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) trial, initiated in 2001, were presented today at the...
- Emitting flashes of light; glittering.